@article{66f0a19f20d04112958efb6341134bd8,
title = "Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients",
abstract = "Objective: To assess the feasibility of enrollment and collecting patient-reported outcome (PRO) data as part of routine clinical urologic care for bladder and prostate cancer patients and examine overall patterns and racial variations in PRO use and symptom reports over time. Subjects/Patients and Methods: We recruited 76 patients (n = 29 Black and n = 47 White) with prostate or bladder cancer at a single, comprehensive cancer center. The majority of prostate cancer patients had intermediate risk (57%) disease and underwent either radiation or prostatectomy. Over half (58%) of bladder cancer patients had muscle invasive disease and underwent cystectomy. Patients were asked to complete PRO symptom surveys using their preferred mode [web- or phone-based interactive voice response (IVR)]. Symptom summary reports were shared with providers during visits. Surveys were completed at 3 time points and assessed urinary, sexual, gastrointestinal, anxiety/depression, and sleep symptoms. Feasibility of enrollment and survey completion were calculated, and linear mixed effects models estimated differences in outcomes by race and time. Results: Sixty three percent of study participants completed all PRO measures at all 3 time points. Black patients were more likely to select IVR as their survey mode (40% vs. 13%, P < 0.05), and less likely to complete all surveys (55% vs. 74%, P = 0.13). Patients using IVR were also less likely to complete all surveys (41% vs. 69%, P = 0.046). Conclusions: Reported preferences for survey mode and completion rates differ by race, which may influence survey completion rates and highlight potential obstacles for equitable implementation of PROs into clinical care.",
keywords = "Bladder cancer, Patient-reported outcomes (PROs), Prostate cancer, Racial disparities",
author = "Smith, {Angela B.} and Samuel, {Cleo A.} and McCabe, {Sean D.} and Allison Deal and Mattias Jonsson and Mueller, {Dana E.} and Mahbooba, {Zahra M.} and Bennett, {Antonia V.} and Chung, {Arlene E.} and Nielsen, {Matthew E.} and Tan, {Hung Jui} and Eric Wallen and Raj Pruthi and Andrew Wang and Ethan Basch and Reeve, {Bryce B.} and Chen, {Ronald C.}",
note = "Funding Information: AS reports funding from PCORI and AHRQ and compensation as a consultant for Merck and scientific advisory board for Urogen and Photocure during the study time period, all of which were outside the relevant work. CAS reports research funding from NCI and Pfizer for work unrelated to this study. AC reports research funding from NIH, PCORI, Healthwise, and Eli Lilly & Company (via Northwestern University) during the study period, all of which were outside of the scope of this current research. HT reports research funding from the American Cancer Society. MN reports compensation from the American College of Physicians High Value Care Task Force (consultant) and Grand Rounds (Medical Advisory Board) outside of the work in this manuscript. Funding Information: This project made use of systems and services provided by the Patient-Reported Outcomes Core (PRO Core; pro.unc.edu) at the Lineberger Comprehensive Cancer Center (LCCC) of the University of North Carolina. PRO Core is funded in part by a National Cancer Institute Cancer Center Core Support Grant ( 5-P30-CA016086 ) and the University Cancer Research Fund of North Carolina. The LCCC Bioinformatics Core provides the computational infrastructure for the PRO Core system. Funding Information: This work was funded by an administrative supplement to the NCI grant R01CA174453 “PROMIS Validation in Prospective Population-based Prostate Cancer Research Study”. Funding Information: This work was funded by an administrative supplement to the NCI grant R01CA174453 ?PROMIS Validation in Prospective Population-based Prostate Cancer Research Study?.This project made use of systems and services provided by the Patient-Reported Outcomes Core (PRO Core; pro.unc.edu) at the Lineberger Comprehensive Cancer Center (LCCC) of the University of North Carolina. PRO Core is funded in part by a National Cancer Institute Cancer Center Core Support Grant (5-P30-CA016086) and the University Cancer Research Fund of North Carolina. The LCCC Bioinformatics Core provides the computational infrastructure for the PRO Core system. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2021",
month = jan,
doi = "10.1016/j.urolonc.2020.06.030",
language = "English (US)",
volume = "39",
pages = "77.e1--77.e8",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",
}